ProMIS Neurosciences, Inc. Quarterly report [Sections 13 or 15(d)]

NET LOSS PER SHARE - Outstanding potentially dilutive common shares (Details) - shares	9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025
NET LOSS PER SHARE
Dilutive common shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive	10,191,123	2,756,973
Options issued and outstanding under stock option plan
NET LOSS PER SHARE
Dilutive common shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive	1,052,439	181,314
Warrants
NET LOSS PER SHARE
Dilutive common shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive	9,138,642	2,575,617
Deferred share units
NET LOSS PER SHARE
Dilutive common shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive	42	42